Targeted therapy for gynecologic cancers: Toward the era of precision medicine

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Molecular biology advances have enabled targeted cancer therapies.
• Targeted agents, including monoclonal antibodies and small molecules, focus on cancer cell signaling pathways.
• Traditional chemotherapy inhibits DNA synthesis and mitosis, unlike targeted agents.

Purpose of the Study:

• To review recent advances in targeted therapies for gynecologic cancers.
• To highlight the role of angiogenesis inhibitors, PARP inhibitors, and immune checkpoint inhibitors.
• To emphasize the importance of cancer genomics and biomarkers in precision medicine for gynecologic cancers.

Main Methods:

• Review of recent literature on targeted therapies in gynecologic oncology.
• Analysis of drug mechanisms targeting cancer signaling pathways, angiogenesis, homologous recombination deficiency, and immune checkpoints.
• Discussion of clinical applications and outcomes in ovarian, cervical, and other gynecologic cancers.

Main Results:

• Anti-VEGF antibodies are used for advanced/recurrent ovarian and cervical cancers.
• PARP inhibitors are approved for maintenance therapy in platinum-sensitive ovarian cancer.
• Immune checkpoint inhibitors show durable responses in platinum-resistant ovarian cancer.

Conclusions:

• Targeted therapies represent a significant advancement in gynecologic cancer treatment.
• Precision medicine, guided by genomics and biomarkers, is crucial for personalized treatment strategies.
• Continued research into novel targeted agents and immunotherapies holds promise for improving women's health in gynecologic oncology.